Onabotulinumtoxin A

DRUG6 trials

Sponsors

Oslo University Hospital, Johns Hopkins University, Wake Forest University Health Sciences, Jamie Bartley, DO, Northwell Health

Conditions

Fine LinesInterstitial CystitisPelvic PainPhotoagingRaynaud's SyndromeSclerodermaSpinal Cord InjuriesStress Urinary Incontinence

Early Phase 1

Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence

SuspendedNCT04984317

Northwell HealthStress Urinary Incontinence

Start: 2022-02-14End: 2027-08-01Target: 20Updated: 2026-01-26

Phase 3

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

CompletedNCT02165111

Johns Hopkins UniversityRaynaud's Syndrome, Scleroderma

Start: 2015-01-31End: 2015-09-30Updated: 2016-12-22

Phase 4

Prevention of Bladder Dysfunction in Acute Spinal Cord Injury

CompletedNCT01698138

Oslo University HospitalSpinal Cord Injuries, Urinary Bladder, Overactive

Start: 2012-09-30End: 2020-12-20Target: 20Updated: 2022-11-23

Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

CompletedNCT02297100

Wake Forest University Health SciencesInterstitial Cystitis

Start: 2014-12-31End: 2018-01-10Updated: 2018-09-05

Unknown Phase

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

CompletedNCT02369068

Jamie Bartley, DOPelvic Pain

Start: 2015-08-31End: 2018-09-24Updated: 2019-07-24

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

CompletedNCT05089851

Revision SkincareFine Lines, Photoaging, Wrinkles

Start: 2020-08-23End: 2021-06-03Updated: 2021-10-28